Journal of Clinical Lipidology · Nov 2026
Oral PCSK9 Inhibition in the Injectable Era: Repositioning Intensive LDL-Cholesterol Lowering in Contemporary Cardiovascular Prevention
By Abdulle AH, Abdi DA, Bulhan OA et al.
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is an established strategy for intensive low-density lipoprotein cholesterol (LDL-C) lowering, but clinical use has historically relied on injectable therapies. The approval of enlicitide as the first oral PCSK9 inhibitor introduces a new therapeutic option and raises the question of how oral PCSK9 inhibition should be positioned alongside established injectable strategies. Methods This contemporary review integrates genetic evidence, randomized clinical trials, long-term safety data, cardiovascular-outcomes studies, guideline recommendations, adherence and access literature, and phase 1–3 evidence for oral PCSK9 inhibition, with emphasis on enlicitide and emerging small-molecule approaches. Results Enlicitide has produced LDL-C reductions of approximately 55%–65% across phase 2 and phase 3 studies, with sustained efficacy through 52 weeks and substantial reductions in other atherogenic lipoproteins. Active-comparator evidence demonstrates greater LDL-C lowering than ezetimibe, bempedoic acid, or their combination. Evolocumab and alirocumab retain established cardiovascular-outcomes evidence and the longest safety follow-up, whereas definitive cardiovascular-outcomes evidence for enlicitide and inclisiran remains pending. Oral delivery removes the need for injection but introduces daily administration considerations, while access, adherence, and persistence remain important across PCSK9-directed therapies. Conclusions Oral PCSK9 inhibition expands the therapeutic options available for intensive LDL-C lowering rather than replacing injectable strategies. Its clinical position will depend on cardiovascular risk, residual LDL-C burden, strength of outcomes evidence, treatment preference, adherence, access, and long-term safety. Ongoing cardiovascular-outcomes trials will clarify how oral PCSK9 inhibition should be integrated into contemporary cardiovascular prevention.